Erschienen in:
29.05.2019 | ASO Author Reflections
ASO Author Reflections: Optimal Management of Anal Adenocarcinoma: Clues from a Large, National Database
verfasst von:
Gary D. Lewis, MD, Bin S. Teh, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2019
Einloggen, um Zugang zu erhalten
Excerpt
Adenocarcinoma of the anus is a rare subtype of anal cancer and is thought to represent between 5 and 10% of all anal cancer cases.
1 Previous studies have reported that anal adenocarcinoma (AA) carries a worse prognosis when compared with anal squamous cell carcinoma (AS).
1,2 However, due to the rarity of this disease, there are currently no evidence-based treatment guidelines. AS is treated with definitive chemoradiation (CRT). In contrast, AA has typically been treated similarly to a low-lying rectal adenocarcinoma, i.e. trimodality therapy with neoadjuvant CRT followed by abdominoperineal resection (APR). Unfortunately, the data on this treatment strategy are limited to retrospective institutional reviews. …